GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]

 SCF_HUMAN               Reviewed;         273 AA.
P21583; A0AV09; A8K2Q4; B7ZLM4; Q16487; Q68DZ2; Q7M4N8; Q9UQK7;
01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
01-MAY-1991, sequence version 1.
03-JUL-2019, entry version 181.
RecName: Full=Kit ligand;
AltName: Full=Mast cell growth factor;
Short=MGF;
AltName: Full=Stem cell factor;
Short=SCF;
AltName: Full=c-Kit ligand;
Contains:
RecName: Full=Soluble KIT ligand;
Short=sKITLG;
Flags: Precursor;
Name=KITLG; Synonyms=MGF, SCF;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=2208279; DOI=10.1016/0092-8674(90)90301-T;
Martin F.H., Suggs S.V., Langley K.E., Lu H.S., Ting J., Okino K.H.,
Morris C.F., McNiece I.K., Jacobsen F.W., Mendiaz E.A., Birkett N.C.,
Smith K.A., Johnson M.J., Parker V.P., Flores J.C., Patel A.C.,
Fisher E.F., Erjavec H.O., Herrera C.J., Wypych J., Sachdev R.K.,
Pope J.A., Leslie I., Wen D., Lin C.-H., Cupples R.L., Zsebo K.M.;
"Primary structure and functional expression of rat and human stem
cell factor DNAs.";
Cell 63:203-211(1990).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
PubMed=1724381;
Anderson D.M., Williams D.E., Tushinski R., Gimpel S., Eisenman J.,
Cannizzaro L.A., Aronson M., Croce C.M., Huebner K., Cosman D.;
"Alternate splicing of mRNAs encoding human mast cell growth factor
and localization of the gene to chromosome 12q22-q24.";
Cell Growth Differ. 2:373-378(1991).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
PubMed=10049787; DOI=10.1006/bbrc.1999.0260;
Blair H.C., Julian B.A., Cao X., Jordan S.E., Dong S.S.;
"Parathyroid hormone-regulated production of stem cell factor in human
osteoblasts and osteoblast-like cells.";
Biochem. Biophys. Res. Commun. 255:778-784(1999).
[4]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
Han C., Peng X., Yuan J., Qiang B.;
Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
TISSUE=Tongue, and Trachea;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
TISSUE=Amygdala;
PubMed=17974005; DOI=10.1186/1471-2164-8-399;
Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
"The full-ORF clone resource of the German cDNA consortium.";
BMC Genomics 8:399-399(2007).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
TISSUE=Brain, and Colon;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[9]
PROTEIN SEQUENCE OF 26-40; 64-79; 87-102; 110-149 AND 154-190 (ISOFORM
1), DISULFIDE BONDS, SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND
GLYCOSYLATION AT ASN-90; ASN-118; ASN-145; SER-167; THR-168 AND
THR-180.
PubMed=1381905; DOI=10.1016/0003-9861(92)90106-7;
Lu H.S., Clogston C.L., Wypych J., Parker V.P., Lee T.D., Swiderek K.,
Baltera R.F. Jr., Patel A.C., Chang D.C., Brankow D.W., Liu X.-D.,
Ogden S.G., Karkare S.B., Hu S.S., Zsebo K.M., Langley K.E.;
"Post-translational processing of membrane-associated recombinant
human stem cell factor expressed in Chinese hamster ovary cells.";
Arch. Biochem. Biophys. 298:150-158(1992).
[10]
NUCLEOTIDE SEQUENCE [MRNA] OF 167-248 (ISOFORM 2).
PubMed=1379846;
Toyota M., Hinoda Y., Itoh F., Tsujisaki M., Imai K., Yachi A.;
"Expression of two types of kit ligand mRNAs in human tumor cells.";
Int. J. Hematol. 55:301-304(1992).
[11]
REVIEW.
PubMed=10582791; DOI=10.1093/humupd/5.5.535;
Mauduit C., Hamamah S., Benahmed M.;
"Stem cell factor/c-kit system in spermatogenesis.";
Hum. Reprod. Update 5:535-545(1999).
[12]
REVIEW.
PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
Ronnstrand L.;
"Signal transduction via the stem cell factor receptor/c-Kit.";
Cell. Mol. Life Sci. 61:2535-2548(2004).
[13]
REVIEW.
PubMed=15625120; DOI=10.1634/stemcells.2004-0117;
Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.;
"Normal and oncogenic forms of the receptor tyrosine kinase kit.";
Stem Cells 23:16-43(2005).
[14]
INVOLVEMENT IN SHEP7.
PubMed=17952075; DOI=10.1038/ng.2007.13;
Sulem P., Gudbjartsson D.F., Stacey S.N., Helgason A., Rafnar T.,
Magnusson K.P., Manolescu A., Karason A., Palsson A., Thorleifsson G.,
Jakobsdottir M., Steinberg S., Palsson S., Jonasson F.,
Sigurgeirsson B., Thorisdottir K., Ragnarsson R.,
Benediktsdottir K.R., Aben K.K., Kiemeney L.A., Olafsson J.H.,
Gulcher J., Kong A., Thorsteinsdottir U., Stefansson K.;
"Genetic determinants of hair, eye and skin pigmentation in
Europeans.";
Nat. Genet. 39:1443-1452(2007).
[15]
POLYMORPHISM LINKED TO BLOND HAIR COLOR.
PubMed=24880339; DOI=10.1038/ng.2991;
Guenther C.A., Tasic B., Luo L., Bedell M.A., Kingsley D.M.;
"A molecular basis for classic blond hair color in Europeans.";
Nat. Genet. 46:748-752(2014).
[16]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), AND DISULFIDE BONDS.
PubMed=10880433; DOI=10.1093/emboj/19.13.3192;
Jiang X., Gurel O., Mendiaz E.A., Stearns G.W., Clogston C.L.,
Lu H.S., Osslund T.D., Syed R.S., Langley K.E., Hendrickson W.A.;
"Structure of the active core of human stem cell factor and analysis
of binding to its receptor kit.";
EMBO J. 19:3192-3203(2000).
[17]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-166, AND DISULFIDE BONDS.
PubMed=10884405; DOI=10.1073/pnas.97.14.7732;
Zhang Z., Zhang R., Joachimiak A., Schlessinger J., Kong X.P.;
"Crystal structure of human stem cell factor: implication for stem
cell factor receptor dimerization and activation.";
Proc. Natl. Acad. Sci. U.S.A. 97:7732-7737(2000).
[18]
X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 26-166 IN COMPLEX WITH KIT,
AND DISULFIDE BONDS.
PubMed=17662946; DOI=10.1016/j.cell.2007.05.055;
Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I.,
Schlessinger J.;
"Structural basis for activation of the receptor tyrosine kinase KIT
by stem cell factor.";
Cell 130:323-334(2007).
[19]
VARIANT FPHH SER-36, AND CHARACTERIZATION OF VARIANT FPHH SER-36.
PubMed=19375057; DOI=10.1016/j.ajhg.2009.03.019;
Wang Z.-Q., Si L., Tang Q., Lin D., Fu Z., Zhang J., Cui B., Zhu Y.,
Kong X., Deng M., Xia Y., Xu H., Le W., Hu L., Kong X.;
"Gain-of-function mutation of KIT ligand on melanin synthesis causes
familial progressive hyperpigmentation.";
Am. J. Hum. Genet. 84:672-677(2009).
[20]
VARIANT DCUA 67-HIS-CYS-68 DELINS ARG, CHARACTERIZATION OF VARIANT
DCUA 67-HIS-CYS-68 DELINS ARG, INVOLVEMENT IN DCUA, VARIANT VAL-104,
CHARACTERIZATION OF VARIANT VAL-104, AND SUBCELLULAR LOCATION (ISOFORM
2).
PubMed=26522471; DOI=10.1016/j.ajhg.2015.09.011;
Baylor-Hopkins Center for Mendelian Genomics;
Zazo Seco C., Serrao de Castro L., van Nierop J.W., Morin M.,
Jhangiani S., Verver E.J., Schraders M., Maiwald N., Wesdorp M.,
Venselaar H., Spruijt L., Oostrik J., Schoots J., van Reeuwijk J.,
Lelieveld S.H., Huygen P.L., Insenser M., Admiraal R.J.,
Pennings R.J., Hoefsloot L.H., Arias-Vasquez A., de Ligt J.,
Yntema H.G., Jansen J.H., Muzny D.M., Huls G., van Rossum M.M.,
Lupski J.R., Moreno-Pelayo M.A., Kunst H.P., Kremer H.;
"Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and
Unilateral Hearing Loss and Waardenburg Syndrome Type 2.";
Am. J. Hum. Genet. 97:647-660(2015).
-!- FUNCTION: Ligand for the receptor-type protein-tyrosine kinase
KIT. Plays an essential role in the regulation of cell survival
and proliferation, hematopoiesis, stem cell maintenance,
gametogenesis, mast cell development, migration and function, and
in melanogenesis. KITLG/SCF binding can activate several signaling
pathways. Promotes phosphorylation of PIK3R1, the regulatory
subunit of phosphatidylinositol 3-kinase, and subsequent
activation of the kinase AKT1. KITLG/SCF and KIT also transmit
signals via GRB2 and activation of RAS, RAF1 and the MAP kinases
MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation
of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT
promote activation of PLCG1, leading to the production of the
cellular signaling molecules diacylglycerol and inositol 1,4,5-
trisphosphate. KITLG/SCF acts synergistically with other
cytokines, probably interleukins.
-!- SUBUNIT: Homodimer, non-covalently linked (Probable).
Heterotetramer with KIT, binding two KIT molecules; thereby
mediates KIT dimerization and subsequent activation by
autophosphorylation. {ECO:0000269|PubMed:17662946, ECO:0000305}.
-!- INTERACTION:
P10721:KIT; NbExp=2; IntAct=EBI-1379527, EBI-1379503;
-!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
membrane protein.
-!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
{ECO:0000269|PubMed:26522471}. Cytoplasm, cytoskeleton
{ECO:0000250}. Cell membrane {ECO:0000269|PubMed:26522471};
Single-pass type I membrane protein {ECO:0000250}. Cell
projection, lamellipodium {ECO:0000269|PubMed:26522471}. Cell
projection, filopodium {ECO:0000269|PubMed:26522471}.
-!- SUBCELLULAR LOCATION: Soluble KIT ligand: Secreted.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=3;
Name=1; Synonyms=SCF248;
IsoId=P21583-1; Sequence=Displayed;
Name=2; Synonyms=SCF220;
IsoId=P21583-2; Sequence=VSP_006022;
Name=3;
IsoId=P21583-3; Sequence=VSP_032762, VSP_032763;
Note=No experimental confirmation available.;
-!- DEVELOPMENTAL STAGE: Acts in the early stages of hematopoiesis.
-!- PTM: A soluble form (sKITLG) is produced by proteolytic processing
of isoform 1 in the extracellular domain.
{ECO:0000269|PubMed:1381905}.
-!- PTM: Found in two differentially glycosylated forms, LMW-SCF and
HMW-SCF. LMW-SCF is fully N-glycosylated at Asn-145, partially N-
glycosylated at Asn-90, O-glycosylated at Ser-167, Thr-168 and
Thr-180, and not glycosylated at Asn-97 or Asn-118. HMW-SCF is N-
glycosylated at Asn-118, Asn-90 and Asn-145, O-glycosylated at
Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97.
{ECO:0000269|PubMed:1381905}.
-!- PTM: A soluble form exists as a cleavage product of the
extracellular domain. {ECO:0000269|PubMed:1381905}.
-!- POLYMORPHISM: Genetic variants in KITLG define the skin/hair/eye
pigmentation variation locus 7 (SHEP7) [MIM:611664]. Hair, eye and
skin pigmentation are among the most visible examples of human
phenotypic variation, with a broad normal range that is subject to
substantial geographic stratification. In the case of skin,
individuals tend to have lighter pigmentation with increasing
distance from the equator. By contrast, the majority of variation
in human eye and hair color is found among individuals of European
ancestry, with most other human populations fixed for brown eyes
and black hair.
-!- POLYMORPHISM: A non-coding SNP (dbSNP:rs12821256) has been shown
to be associated with classic blond hair color in Europeans. This
SNP is located 350 kb upstream from KITLG, in an enhancer
specifically active in the hair follicle environment. It alters a
LEF1 binding site, reducing LEF1 responsiveness in cultured
keratinocytes. This SNP is not associated with eye pigmentation.
It is most prevalent in Northern Europe (PubMed:24880339).
{ECO:0000269|PubMed:24880339}.
-!- DISEASE: Hyperpigmentation with or without hypopigmentation,
familial progressive (FPHH) [MIM:145250]: A disorder characterized
by hyperpigmented patches in the skin, present in early infancy
and increasing in size and number with age. Hyperpigmentation has
variable intensity, and sometimes is associated with cafe-au-lait
macules and larger hypopigmented ash-leaf macules.
{ECO:0000269|PubMed:19375057}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- DISEASE: Deafness, congenital, unilateral or asymmetric (DCUA)
[MIM:616697]: An autosomal dominant form of non-syndromic,
sensorineural deafness characterized by inability to hear
affecting one ear. Some patients suffers from asymmetric,
bilateral hearing loss. {ECO:0000269|PubMed:26522471}. Note=The
disease is caused by mutations affecting the gene represented in
this entry.
-!- SIMILARITY: Belongs to the SCF family. {ECO:0000305}.
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/MGFID142.html";
-!- WEB RESOURCE: Name=Protein Spotlight; Note=two's company - Issue
163 of August 2014;
URL="https://web.expasy.org/spotlight/back_issues/163/";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
-----------------------------------------------------------------------
EMBL; M59964; AAA85450.1; -; mRNA.
EMBL; AF119835; AAD22048.1; -; mRNA.
EMBL; AF400436; AAK92485.1; -; mRNA.
EMBL; AF400437; AAK92486.1; -; mRNA.
EMBL; AK290319; BAF83008.1; -; mRNA.
EMBL; AK293002; BAF85691.1; -; mRNA.
EMBL; CR749222; CAH18078.1; -; mRNA.
EMBL; CH471054; EAW97417.1; -; Genomic_DNA.
EMBL; BC069733; AAH69733.1; -; mRNA.
EMBL; BC069783; AAH69783.1; -; mRNA.
EMBL; BC069797; AAH69797.1; -; mRNA.
EMBL; BC074725; AAH74725.1; -; mRNA.
EMBL; BC126166; AAI26167.1; -; mRNA.
EMBL; BC143899; AAI43900.1; -; mRNA.
EMBL; S42571; AAB22846.2; -; mRNA.
CCDS; CCDS31867.1; -. [P21583-2]
CCDS; CCDS31868.1; -. [P21583-1]
PIR; A35974; A35974.
PIR; B61190; B61190.
PIR; S29052; S29052.
RefSeq; NP_000890.1; NM_000899.4. [P21583-1]
RefSeq; NP_003985.2; NM_003994.5. [P21583-2]
PDB; 1EXZ; X-ray; 2.30 A; A/B/C/D=26-166.
PDB; 1SCF; X-ray; 2.20 A; A/B/C/D=1-273.
PDB; 2E9W; X-ray; 3.50 A; C/D=26-166.
PDBsum; 1EXZ; -.
PDBsum; 1SCF; -.
PDBsum; 2E9W; -.
SMR; P21583; -.
BioGrid; 110410; 9.
IntAct; P21583; 3.
STRING; 9606.ENSP00000228280; -.
BindingDB; P21583; -.
ChEMBL; CHEMBL2346489; -.
iPTMnet; P21583; -.
PhosphoSitePlus; P21583; -.
BioMuta; KITLG; -.
DMDM; 134289; -.
jPOST; P21583; -.
MaxQB; P21583; -.
PaxDb; P21583; -.
PeptideAtlas; P21583; -.
PRIDE; P21583; -.
ProteomicsDB; 53880; -.
ProteomicsDB; 53881; -. [P21583-2]
ProteomicsDB; 53882; -. [P21583-3]
DNASU; 4254; -.
Ensembl; ENST00000228280; ENSP00000228280; ENSG00000049130. [P21583-1]
Ensembl; ENST00000347404; ENSP00000054216; ENSG00000049130. [P21583-2]
Ensembl; ENST00000644744; ENSP00000495951; ENSG00000049130. [P21583-1]
GeneID; 4254; -.
KEGG; hsa:4254; -.
UCSC; uc001tav.4; human. [P21583-1]
CTD; 4254; -.
DisGeNET; 4254; -.
GeneCards; KITLG; -.
HGNC; HGNC:6343; KITLG.
HPA; HPA070395; -.
MalaCards; KITLG; -.
MIM; 145250; phenotype.
MIM; 184745; gene.
MIM; 611664; phenotype.
MIM; 616697; phenotype.
neXtProt; NX_P21583; -.
OpenTargets; ENSG00000049130; -.
Orphanet; 90635; Autosomal dominant non-syndromic sensorineural deafness type DFNA.
Orphanet; 280628; Familial progressive hyper- and hypopigmentation.
Orphanet; 79146; Familial progressive hyperpigmentation.
Orphanet; 363494; Non-seminomatous germ cell tumor of testis.
Orphanet; 895; Waardenburg syndrome type 2.
PharmGKB; PA30129; -.
eggNOG; ENOG410IF3Y; Eukaryota.
eggNOG; ENOG410XYQR; LUCA.
GeneTree; ENSGT00390000018272; -.
InParanoid; P21583; -.
KO; K05461; -.
OMA; VKTKGIC; -.
OrthoDB; 1083457at2759; -.
PhylomeDB; P21583; -.
TreeFam; TF330811; -.
Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
Reactome; R-HSA-1433557; Signaling by SCF-KIT.
Reactome; R-HSA-1433559; Regulation of KIT signaling.
Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
SIGNOR; P21583; -.
ChiTaRS; KITLG; human.
EvolutionaryTrace; P21583; -.
GeneWiki; Stem_cell_factor; -.
GenomeRNAi; 4254; -.
PMAP-CutDB; P21583; -.
PRO; PR:P21583; -.
Proteomes; UP000005640; Chromosome 12.
Bgee; ENSG00000049130; Expressed in 208 organ(s), highest expression level in visceral pleura.
ExpressionAtlas; P21583; baseline and differential.
Genevisible; P21583; HS.
GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
GO; GO:0005576; C:extracellular region; TAS:Reactome.
GO; GO:0005615; C:extracellular space; IEA:Ensembl.
GO; GO:0030175; C:filopodium; IDA:UniProtKB.
GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
GO; GO:0008083; F:growth factor activity; IEA:UniProtKB-KW.
GO; GO:0005173; F:stem cell factor receptor binding; IBA:GO_Central.
GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
GO; GO:0035162; P:embryonic hemopoiesis; IDA:DFLAT.
GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
GO; GO:0033026; P:negative regulation of mast cell apoptotic process; IEA:Ensembl.
GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
GO; GO:1901534; P:positive regulation of hematopoietic progenitor cell differentiation; TAS:GO_Central.
GO; GO:1902035; P:positive regulation of hematopoietic stem cell proliferation; IEA:Ensembl.
GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
GO; GO:0070668; P:positive regulation of mast cell proliferation; IEA:Ensembl.
GO; GO:0045636; P:positive regulation of melanocyte differentiation; IEA:Ensembl.
GO; GO:0002763; P:positive regulation of myeloid leukocyte differentiation; IEA:Ensembl.
GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
GO; GO:0051897; P:positive regulation of protein kinase B signaling; TAS:Reactome.
GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IEA:Ensembl.
DisProt; DP00917; -.
InterPro; IPR009079; 4_helix_cytokine-like_core.
InterPro; IPR003452; SCF.
PANTHER; PTHR11574; PTHR11574; 1.
Pfam; PF02404; SCF; 1.
PIRSF; PIRSF015599; SCF; 1.
SUPFAM; SSF47266; SSF47266; 1.
1: Evidence at protein level;
3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
Cell projection; Complete proteome; Cytoplasm; Cytoskeleton; Deafness;
Direct protein sequencing; Disease mutation; Disulfide bond;
Glycoprotein; Growth factor; Membrane; Non-syndromic deafness;
Polymorphism; Reference proteome; Secreted; Signal; Transmembrane;
Transmembrane helix.
SIGNAL 1 25
CHAIN 26 273 Kit ligand.
/FTId=PRO_0000031913.
CHAIN 26 190 Soluble KIT ligand.
/FTId=PRO_0000403391.
TOPO_DOM 26 214 Extracellular. {ECO:0000255}.
TRANSMEM 215 237 Helical. {ECO:0000255}.
TOPO_DOM 238 273 Cytoplasmic. {ECO:0000255}.
SITE 97 97 Not glycosylated.
CARBOHYD 90 90 N-linked (GlcNAc...) asparagine; partial.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 118 118 N-linked (GlcNAc...) asparagine; partial.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 145 145 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 167 167 O-linked (GalNAc...) serine.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 168 168 O-linked (GalNAc...) threonine.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 180 180 O-linked (GalNAc...) threonine.
{ECO:0000269|PubMed:1381905}.
CARBOHYD 195 195 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
DISULFID 29 114
DISULFID 68 163
VAR_SEQ 1 35 Missing (in isoform 3).
{ECO:0000303|PubMed:17974005}.
/FTId=VSP_032762.
VAR_SEQ 36 43 NVKDVTKL -> MPSCLAAQ (in isoform 3).
{ECO:0000303|PubMed:17974005}.
/FTId=VSP_032763.
VAR_SEQ 174 202 DSRVSVTKPFMLPPVAASSLRNDSSSSNR -> G (in
isoform 2). {ECO:0000303|PubMed:10049787,
ECO:0000303|PubMed:1379846,
ECO:0000303|PubMed:14702039,
ECO:0000303|PubMed:15489334,
ECO:0000303|PubMed:1724381,
ECO:0000303|Ref.4}.
/FTId=VSP_006022.
VARIANT 36 36 N -> S (in FPHH; gain-of-function
mutation; sKITLG reveales that the mutant
Ser-36 sKITLG increases the content of
the melanin by 109% compared with the
wild-type sKITLG; tyrosinase activity is
significantly increased by the mutant
sKITLG compared to wild-type control;
dbSNP:rs121918653).
{ECO:0000269|PubMed:19375057}.
/FTId=VAR_063237.
VARIANT 54 54 T -> A (in dbSNP:rs3741457).
/FTId=VAR_042652.
VARIANT 67 68 HC -> R (in DCUA; loss of cell membrane
association).
{ECO:0000269|PubMed:26522471}.
/FTId=VAR_076222.
VARIANT 104 104 L -> V (found in a patient with
Waardenburg syndrome type 2 (WS2) and
hearing loss; unknown pathological
significance; reduces secretion;
dbSNP:rs864309655).
{ECO:0000269|PubMed:26522471}.
/FTId=VAR_076223.
VARIANT 210 210 D -> Y (in dbSNP:rs41283112).
/FTId=VAR_063238.
VARIANT 232 232 F -> Y (in dbSNP:rs12721563).
/FTId=VAR_042653.
CONFLICT 55 55 L -> S (in Ref. 3; AAD22048 and 4;
AAK92486). {ECO:0000305}.
CONFLICT 128 128 K -> R (in Ref. 3; AAD22048 and 4;
AAK92486). {ECO:0000305}.
CONFLICT 134 134 L -> F (in Ref. 3; AAD22048 and 4;
AAK92486). {ECO:0000305}.
HELIX 30 32 {ECO:0000244|PDB:2E9W}.
HELIX 37 46 {ECO:0000244|PDB:1SCF}.
STRAND 53 56 {ECO:0000244|PDB:1SCF}.
TURN 59 63 {ECO:0000244|PDB:1SCF}.
HELIX 66 68 {ECO:0000244|PDB:1SCF}.
HELIX 70 85 {ECO:0000244|PDB:1SCF}.
STRAND 92 94 {ECO:0000244|PDB:2E9W}.
HELIX 97 114 {ECO:0000244|PDB:1SCF}.
STRAND 120 122 {ECO:0000244|PDB:1EXZ}.
STRAND 132 135 {ECO:0000244|PDB:1SCF}.
HELIX 137 149 {ECO:0000244|PDB:1SCF}.
TURN 150 152 {ECO:0000244|PDB:1SCF}.
STRAND 157 160 {ECO:0000244|PDB:1SCF}.
SEQUENCE 273 AA; 30899 MW; 19FD362CB59C6607 CRC64;
MKKTQTWILT CIYLQLLLFN PLVKTEGICR NRVTNNVKDV TKLVANLPKD YMITLKYVPG
MDVLPSHCWI SEMVVQLSDS LTDLLDKFSN ISEGLSNYSI IDKLVNIVDD LVECVKENSS
KDLKKSFKSP EPRLFTPEEF FRIFNRSIDA FKDFVVASET SDCVVSSTLS PEKDSRVSVT
KPFMLPPVAA SSLRNDSSSS NRKAKNPPGD SSLHWAAMAL PALFSLIIGF AFGALYWKKR
QPSLTRAVEN IQINEEDNEI SMLQEKEREF QEV


Related products :

Catalog number Product name Quantity
U0120m CLIA c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Mouse,Mus musculus,SCF,Sl,Slf,Steel factor,Stem cell factor 96T
E0120m ELISA c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Mouse,Mus musculus,SCF,Sl,Slf,Steel factor,Stem cell factor 96T
E0120m ELISA kit c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Mouse,Mus musculus,SCF,Sl,Slf,Steel factor,Stem cell factor 96T
E0120r ELISA c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Rat,Rattus norvegicus,SCF,Stem cell factor 96T
U0120r CLIA c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Rat,Rattus norvegicus,SCF,Stem cell factor 96T
E0120r ELISA kit c-Kit ligand,Hematopoietic growth factor KL,Kit ligand,Kitl,Kitlg,Mast cell growth factor,MGF,Mgf,Rat,Rattus norvegicus,SCF,Stem cell factor 96T
100-097 SCF Human Host: E. coli KITLG; SF; MGF; SCF; FPH2; KL-1; Kitl; SHEP7; kit-ligand; stem cell factor; Mast cell growth factor; c-Kit ligand 10
100-097-SC SCF Human Host: E. coli KITLG; SF; MGF; SCF; FPH2; KL-1; Kitl; SHEP7; kit-ligand; stem cell factor; Mast cell growth factor; c-Kit ligand 50
100-097S SCF Human Host: E. coli KITLG; SF; MGF; SCF; FPH2; KL-1; Kitl; SHEP7; kit-ligand; stem cell factor; Mast cell growth factor; c-Kit ligand 2
E0120h ELISA kit c-Kit ligand,Homo sapiens,Human,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,SCF,SCF,Stem cell factor 96T
E0120h ELISA c-Kit ligand,Homo sapiens,Human,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,SCF,SCF,Stem cell factor 96T
U0120h CLIA c-Kit ligand,Homo sapiens,Human,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,SCF,SCF,Stem cell factor 96T
E0120b ELISA Bos taurus,Bovine,c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
U0120b CLIA Bos taurus,Bovine,c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
E0120b ELISA kit Bos taurus,Bovine,c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
E0120p ELISA kit c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,Pig,SCF,Stem cell factor,Sus scrofa 96T
E0120p ELISA c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,Pig,SCF,Stem cell factor,Sus scrofa 96T
U0120p CLIA c-Kit ligand,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,Pig,SCF,Stem cell factor,Sus scrofa 96T
E0120c ELISA Chicken,c-Kit ligand,Gallus gallus,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
U0120c CLIA Chicken,c-Kit ligand,Gallus gallus,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
E0120c ELISA kit Chicken,c-Kit ligand,Gallus gallus,Kit ligand,KITLG,Mast cell growth factor,MGF,SCF,SCF,Stem cell factor 96T
18-783-78902 GOAT ANTI HUMAN STEM CELL FACTOR Biotin - SCF; C-kit ligand; Stem cell factor; SCF; Mast cell growth factor; MGF Polyclonal 0.05 mg
18-783-75592 GOAT ANTI HUMAN STEM CELL FACTOR - SCF; C-kit ligand; Stem cell factor; SCF; Mast cell growth factor; MGF Polyclonal 0.1 mg
E0120c ELISA kit Canis familiaris,Canis lupus familiaris,c-Kit ligand,Dog,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,SCF,Stem cell factor 96T
E0120c ELISA Canis familiaris,Canis lupus familiaris,c-Kit ligand,Dog,Kit ligand,KITLG,Mast cell growth factor,MGF,MGF,SCF,Stem cell factor 96T
Pathways :
WP1899: Regulation of Insulin-like Growth Factor (IGF) Activity by Insulin-like Growth Factor Binding Proteins (IGFBPs)
WP313: Signaling of Hepatocyte Growth Factor Receptor
WP161: Small Ligand GPCRs
WP1789: Binding of RNA by Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs)
WP193: Signaling of Hepatocyte Growth Factor Receptor
WP1046: Signaling of Hepatocyte Growth Factor Receptor
WP2355: Corticotropin-releasing hormone
WP1162: Signaling of Hepatocyte Growth Factor Receptor
WP94: Signaling of Hepatocyte Growth Factor Receptor
WP1235: Signaling of Hepatocyte Growth Factor Receptor
WP353: Small Ligand GPCRs
WP1825: GPCR ligand binding
WP810: Signaling of Hepatocyte Growth Factor Receptor
WP1317: Small Ligand GPCRs
WP1089: Small Ligand GPCRs
WP247: Small Ligand GPCRs
WP927: Signaling of Hepatocyte Growth Factor Receptor
WP1206: Signaling of Hepatocyte Growth Factor Receptor
WP746: Small Ligand GPCRs
WP971: Small Ligand GPCRs
WP444: Signaling of Hepatocyte Growth Factor Receptor
WP853: Small Ligand GPCRs
WP2222: Wnt Signaling in Cell Polarity
WP553: Calcium Regulation in the Cardiac Cell
WP923: Calcium Regulation in the Cardiac Cell

Related Genes :
[Kitlg Kitl Mgf Sl Slf] Kit ligand (Hematopoietic growth factor KL) (Mast cell growth factor) (MGF) (Steel factor) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
[Kitlg Kitl Mgf] Kit ligand (Hematopoietic growth factor KL) (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
[KITLG MGF SCF] Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
[KITLG MGF] Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
[KITLG SCF] Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
[KITLG SCF] Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)] (Fragment)
[KIT SCFR] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)
[Kit Sl] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[KIT] Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)
[kita kit sparse] Mast/stem cell growth factor receptor kita (SCFR) (EC 2.7.10.1) (Tyrosine-protein kinase Kit)
[kit krk1] Mast/stem cell growth factor receptor-related protein Kit (EC 2.7.10.1) (Kit-related kinase 1) (xKrk1) (Tyrosine-protein kinase kit)
[TNFSF13B BAFF BLYS TALL1 TNFSF20 ZTNF4 UNQ401/PRO738] Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form]
[CD40LG CD40L TNFSF5 TRAP] CD40 ligand (CD40-L) (T-cell antigen Gp39) (TNF-related activation protein) (TRAP) (Tumor necrosis factor ligand superfamily member 5) (CD antigen CD154) [Cleaved into: CD40 ligand, membrane form; CD40 ligand, soluble form]
[Faslg Apt1Lg1 Cd95l Fasl Tnfsf6] Tumor necrosis factor ligand superfamily member 6 (CD95 ligand) (CD95-L) (Fas antigen ligand) (Fas ligand) (FasL) (CD antigen CD178) [Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form (Receptor-binding FasL ectodomain) (Soluble Fas ligand) (sFasL); ADAM10-processed FasL form (APL); FasL intracellular domain (FasL ICD) (SPPL2A-processed FasL form) (SPA)]
[Tnfsf11 Opgl Rankl Trance] Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form]
[TNFSF11 OPGL RANKL TRANCE] Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form]
[TNFSF14 HVEML LIGHT UNQ391/PRO726] Tumor necrosis factor ligand superfamily member 14 (Herpes virus entry mediator ligand) (HVEM-L) (Herpesvirus entry mediator ligand) (CD antigen CD258) [Cleaved into: Tumor necrosis factor ligand superfamily member 14, membrane form; Tumor necrosis factor ligand superfamily member 14, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[Tnf Tnfa Tnfsf2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
[TNF TNFA TNFSF2] Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]

Bibliography :